Compounds > bosentan anhydrous
Page last updated: 2024-08-26

bosentan anhydrous and Left Ventricular Hypertrophy

bosentan anhydrous has been researched along with Left Ventricular Hypertrophy in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (42.86)18.2507
2000's4 (57.14)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
deChâtel, R; Ilves, M; Kinnunen, P; Piuhola, J; Ruskoaho, H; Szokodi, I; Vuolteenaho, O1
Barst, R; Channick, R; Dujardin, K; Espinola-Zavaleta, N; Fourme, T; Frantz, R; Galiè, N; Hinderliter, AL; Kronenberg, A; Kurzyna, M; Leconte, I; Manes, A; Nagueh, SF; Pulido, T; Rainisio, M; Rocchi, G; Rubin, L; Simonneau, G; Torbicki, A1
Boheler, KR; Firth, JD; Kaddoura, S; Poole-Wilson, PA; Sugden, PH1
Ertl, G; Fraccarollo, D; Galuppo, P; Gaudron, P; Hu, K1
Attramadal, H; Bjønerheim, R; Grogaard, HK; Kongshaug, H; Oie, E; Smiseth, OA1
Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM1
Inagaki, K; Iwanaga, Y; Kataoka, K; Kihara, Y; Onozawa, Y; Sasayama, S; Yoneda, T1

Trials

1 trial(s) available for bosentan anhydrous and Left Ventricular Hypertrophy

ArticleYear
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
    Journal of the American College of Cardiology, 2003, Apr-16, Volume: 41, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Hypertrophy, Right Ventricular; Male; Middle Aged; Sulfonamides; Ventricular Function, Left; Ventricular Function, Right

2003

Other Studies

6 other study(ies) available for bosentan anhydrous and Left Ventricular Hypertrophy

ArticleYear
Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Animals, Genetically Modified; Benzimidazoles; Biphenyl Compounds; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Myocardial Contraction; Organ Culture Techniques; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; RNA, Messenger; Stress, Mechanical; Sulfonamides; Tetrazoles

2003
Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
    Circulation, 1996, Jun-01, Volume: 93, Issue:11

    Topics: Actins; Administration, Oral; Animals; Animals, Newborn; Atrial Natriuretic Factor; Biomarkers; Body Weight; Bosentan; Cells, Cultured; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Endothelins; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Muscle Proteins; Myocardium; Myosin Heavy Chains; Norepinephrine; Organ Size; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; RNA, Antisense; RNA, Messenger; Sulfonamides

1996
Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling.
    Circulation, 1997, Dec-02, Volume: 96, Issue:11

    Topics: Animals; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Endothelin-1; Female; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Myocardial Infarction; Rats; Rats, Wistar; Receptors, Endothelin; Sulfonamides; Time Factors

1997
ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats.
    The American journal of physiology, 1998, Volume: 275, Issue:3

    Topics: Angiotensinogen; Animals; Bosentan; Coronary Vessels; Endothelin Receptor Antagonists; Gene Expression; Heart Failure; Hypertrophy, Left Ventricular; Ligation; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Endothelin A; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Ventricular Function, Left

1998
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
    Journal of molecular and cellular cardiology, 2001, Volume: 33, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left

2001
Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
    Circulation, 2001, Jul-31, Volume: 104, Issue:5

    Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Progression; Endothelin-1; Endothelins; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Male; Organ Size; Peptidyl-Dipeptidase A; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Survival Analysis; Thiazepines; Time Factors

2001